Glaukos Co. (NYSE:GKOS) Holdings Cut by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. lessened its stake in shares of Glaukos Co. (NYSE:GKOSFree Report) by 3.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 24,423 shares of the medical instruments supplier’s stock after selling 873 shares during the quarter. Oppenheimer Asset Management Inc. owned about 0.05% of Glaukos worth $1,838,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in GKOS. Point72 Asset Management L.P. grew its position in Glaukos by 154.8% in the fourth quarter. Point72 Asset Management L.P. now owns 1,152,600 shares of the medical instruments supplier’s stock worth $50,346,000 after buying an additional 700,200 shares during the last quarter. Balyasny Asset Management L.P. grew its position in Glaukos by 304.3% in the first quarter. Balyasny Asset Management L.P. now owns 691,899 shares of the medical instruments supplier’s stock worth $34,664,000 after buying an additional 520,758 shares during the last quarter. Driehaus Capital Management LLC acquired a new position in Glaukos in the second quarter worth approximately $34,771,000. Norges Bank acquired a new position in Glaukos in the 4th quarter worth approximately $17,593,000. Finally, Iron Triangle Partners LP acquired a new position in Glaukos in the 2nd quarter worth approximately $22,075,000. Institutional investors and hedge funds own 99.04% of the company’s stock.

Insider Buying and Selling

In other news, Director Marc Stapley sold 16,250 shares of the business’s stock in a transaction dated Thursday, December 14th. The shares were sold at an average price of $75.93, for a total transaction of $1,233,862.50. Following the transaction, the director now owns 31,316 shares in the company, valued at approximately $2,377,823.88. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, Director Marc Stapley sold 16,250 shares of the company’s stock in a transaction dated Thursday, December 14th. The shares were sold at an average price of $75.93, for a total value of $1,233,862.50. Following the sale, the director now owns 31,316 shares of the company’s stock, valued at $2,377,823.88. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Alex R. Thurman sold 1,270 shares of the business’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $79.80, for a total transaction of $101,346.00. Following the completion of the transaction, the chief financial officer now owns 55,825 shares in the company, valued at $4,454,835. The disclosure for this sale can be found here. Insiders have sold 258,370 shares of company stock worth $21,543,878 in the last quarter. 7.80% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

GKOS has been the subject of a number of recent analyst reports. Truist Financial reaffirmed a “buy” rating and issued a $100.00 price objective on shares of Glaukos in a research note on Friday, December 29th. Piper Sandler raised their price objective on shares of Glaukos from $90.00 to $105.00 and gave the stock an “overweight” rating in a research note on Friday, December 22nd. Morgan Stanley assumed coverage on shares of Glaukos in a research note on Monday, December 4th. They issued an “equal weight” rating and a $65.00 price objective for the company. TheStreet lowered shares of Glaukos from a “c-” rating to a “d+” rating in a research note on Friday, November 24th. Finally, StockNews.com lowered shares of Glaukos from a “hold” rating to a “sell” rating in a research note on Wednesday, December 6th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $87.30.

Get Our Latest Stock Report on Glaukos

Glaukos Trading Up 2.4 %

Shares of GKOS opened at $93.31 on Wednesday. Glaukos Co. has a one year low of $44.26 and a one year high of $94.77. The company has a current ratio of 5.95, a quick ratio of 5.36 and a debt-to-equity ratio of 0.74. The company’s fifty day moving average price is $80.70 and its 200 day moving average price is $74.42.

About Glaukos

(Free Report)

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.

Recommended Stories

Institutional Ownership by Quarter for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.